Bacterial Flora as a Cause or Treatment of Chronic Diarrhea

Gastroenterology Clinics of North America

Volumn 41, Issue 3, 2012, Pages 581-602

  Scaldaferri, Franco ^a   Pizzoferrato, Marco ^a   Pecere, Silvia ^a   Forte, Fabrizio ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antibiotics; Chronic diarrhea; Gut microbiota; Intestinal homeostasis; Probiotics

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; GALACTOSE OLIGOSACCHARIDE; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; NEOMYCIN; ORNIDAZOLE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFABUTIN; RIFAXIMIN; SALAZOSULFAPYRIDINE; TETRACYCLINE; TINIDAZOLE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; BACTERIAL FLORA; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; BACTERIUM IDENTIFICATION; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; CAUSAL ATTRIBUTION; CHRONIC DIARRHEA; CLOSTRIDIUM DIFFICILE INFECTION; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FLATULENCE; HUMAN; ILEITIS; INTESTINE ABSORPTION; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MONOTHERAPY; MUCOSAL IMMUNITY; NONHUMAN; PATIENT COMPLIANCE; PROPIONIBACTERIUM FREUDENREICHII; REVIEW; SACCHAROMYCES BOULARDII; SPECIES COMPOSITION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BACTERIA; BREATH TESTS; CHRONIC DISEASE; DIARRHEA; HOMEOSTASIS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; PREBIOTICS; PROBIOTICS; RNA, RIBOSOMAL, 16S;

EID: 84865355494     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.06.002     Document Type: Review

References (119)

1. Damman CJ, Surawicz CM. comment to: "the gut microbiota: a microbial arsenal protecting us from infectious and radiation-induced diarrhea" by Sekirov I, Tam NM, Jogova M, et al. Infect Immun 2008;76:4726-36. Gastroenterology 2009;136(2):722-4.
2. Backhed F., Ley R.E., Sonnenburg J.L., et al. Host-bacterial mutualism in the human intestine. Science 2005, 307(5717):1915-1920.
3. Zoetendal E.G., Rajilic-Stojanovic M., de Vos W.M. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008, 57(11):1605-1615.
4. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 2005, 308(5728):1635-1638.
5. Guarner F. Enteric flora in health and disease. Digestion 2006, 73(Suppl 1):5-12.
6. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134(2):577-594.
7. Flint H.J., Bayer E.A., Rincon M.T., et al. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 2008, 6(2):121-131.
8. Backhed F., Manchester J.K., Semenkovich C.F., et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007, 104(3):979-984.
9. Fiocchi C. What is "physiological" intestinal inflammation and how does it differ from "pathological" inflammation?. Inflamm Bowel Dis 2008, 14(Suppl 2):S77-S78.
10. Scaldaferri F., Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007, 8(4):171-178.
11. Payne C.M., Fass R., Bernstein H., et al. Pathogenesis of diarrhea in the adult: diagnostic challenges and life-threatening conditions. Eur J Gastroenterol Hepatol 2006, 18(10):1047-1051.
12. Wood J.D. Effects of bacteria on the enteric nervous system: implications for the irritable bowel syndrome. J Clin Gastroenterol 2007, 41(Suppl 1):S7-S19.
13. Packey C.D., Sartor R.B. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 2009, 22(3):292-301.
14. Donowitz M., Kokke F.T., Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995, 332(11):725-729.
15. American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116(6):1461-1463.
16. Laohachai K.N., Bahadi R., Hardo M.B., et al. The role of bacterial and non-bacterial toxins in the induction of changes in membrane transport: implications for diarrhea. Toxicon 2003, 42(7):687-707.
17. Tomasello G., Bellavia M., Palumbo V.D., et al. From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases?. Ann Ital Chir 2011, 82(5):361-368.
18. de Sablet T., Chassard C., Bernalier-Donadille A., et al. Human microbiota-secreted factors inhibit Shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 2009, 77(2):783-790.
19. Endt K., Stecher B., Chaffron S., et al. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. PLoS Pathog 2010, 6(9):e1001097.
20. Darfeuille-Michaud A., Boudeau J., Bulois P., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127(2):412-421.
21. Rodemann J.F., Dubberke E.R., Reske K.A., et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5(3):339-344.
22. Swidsinski A., Ladhoff A., Pernthaler A., et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122(1):44-54.
23. Frank D.N., St Amand A.L., Feldman R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007, 104(34):13780-13785.
24. Scanlan P.D., Marchesi J.R. Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces. ISME J 2008, 2(12):1183-1193.
25. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95(12):3503-3506.
26. Pimentel M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98(2):412-419.
27. Si J.M., Yu Y.C., Fan Y.J., et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004, 10(12):1802-1805.
28. Matto J., Maunuksela L., Kajander K., et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005, 43(2):213-222.
29. Bradley H.K., Wyatt G.M., Bayliss C.E., et al. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987, 23(1):29-32.
30. Malinen E., Rinttila T., Kajander K., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005, 100(2):373-382.
31. Maukonen J., Matto J., Satokari R., et al. PCR DGGE and RT-PCR DGGE show diversity and short-term temporal stability in the Clostridium coccoides-Eubacterium rectale group in the human intestinal microbiota. FEMS Microbiol Ecol 2006, 58(3):517-528.
32. Swidsinski A., Weber J., Loening-Baucke V., et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005, 43(7):3380-3389.
33. Kassinen A., Krogius-Kurikka L., Makivuokko H., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007, 133(1):24-33.
34. Suau A., Bonnet R., Sutren M., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999, 65(11):4799-4807.
35. Bures J., Cyrany J., Kohoutova D., et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010, 16(24):2978-2990.
36. Gasbarrini A., Corazza G.R., Gasbarrini G., et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 2009, 29(Suppl 1):1-49.
37. Levitt M.D. Production and excretion of hydrogen gas in man. N Engl J Med 1969, 281(3):122-127.
38. FAO/WHO Probiotics in food. Health and nutritional properties and guidelines for evaluation 2006, FAO Food and Nutrition Paper, Rome, p. 85.
39. Laine L., Ahnen D., McClain C., et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000, 14(6):651-668.
40. Neal K.R., Scott H.M., Slack R.C., et al. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996, 312(7028):414-415.
41. Williams C., McColl K.E. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006, 23(1):3-10.
42. Dial S., Alrasadi K., Manoukian C., et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171(1):33-38.
43. Gabrielli M., Bonazzi P., Scarpellini E., et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011, 26(5):889-892.
44. Burcelin R., Serino M., Chabo C., et al. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol 2011, 48(4):257-273.
45. Gareau M.G., Sherman P.M., Walker W.A. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010, 7(9):503-514.
46. Ng S.C., Hart A.L., Kamm M.A., et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009, 15(2):300-310.
47. Otte J.M., Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004, 286(4):G613-G626.
48. Venturi A., Gionchetti P., Rizzello F., et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999, 13(8):1103-1108.
49. Nemcova R. Vet Med (Praha) 1997, 42(1):19-27. [in Slovak].
50. Roberfroid M., Gibson G.R., Hoyles L., et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010, 104(Suppl 2):S1-S63.
51. Macfarlane S., Macfarlane G.T., Cummings J.H. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006, 24(5):701-714.
52. Khanna S., Pardi D.S. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010, 4(4):409-416.
53. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1(2):101-114.
54. Scarpignato C., Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006, 73(Suppl 1):13-27.
55. Hoveyda N., Heneghan C., Mahtani K.R., et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009, 9:15.
56. Ki Cha B., Mun Jung S., Hwan Choi C., et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012, 46(3):220-227.
57. Gawronska A., Dziechciarz P., Horvath A., et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007, 25(2):177-184.
58. Gade J., Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989, 7(1):23-26.
59. Kajander K., Hatakka K., Poussa T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005, 22(5):387-394.
60. Kim H.J., Vazquez Roque M.I., Camilleri M., et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005, 17(5):687-696.
61. Guandalini S., Magazzu G., Chiaro A., et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010, 51(1):24-30.
62. Na X., Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol 2011, 45(Suppl):S154-S158.
63. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128(3):541-551.
64. Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13(10):1143-1147.
65. Ringel-Kulka T., Palsson O.S., Maier D., et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 2011, 45(6):518-525.
66. Williams E.A., Stimpson J., Wang D., et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009, 29(1):97-103.
67. Tsuchiya J., Barreto R., Okura R., et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004, 5(4):169-174.
68. Choi C.H., Jo S.Y., Park H.J., et al. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011, 45(8):679-683.
69. Surawicz C.M., Elmer G.W., Speelman P., et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989, 96(4):981-988.
70. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995, 90(3):439-448.
71. Can M., Besirbellioglu B.A., Avci I.Y., et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit 2006, 12(4):PI19-PI22.
72. Bleichner G., Blehaut H., Mentec H., et al. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med 1997, 23(5):517-523.
73. Cremonini F., Di Caro S., Covino M., et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002, 97(11):2744-2749.
74. Vanderhoof J.A., Whitney D.B., Antonson D.L., et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999, 135(5):564-568.
75. Siitonen S., Vapaatalo H., Salminen S., et al. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Ann Med 1990, 22(1):57-59.
76. Cimperman L., Bayless G., Best K., et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 2011, 45(9):785-789.
77. Ruszczynski M., Radzikowski A., Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther 2008, 28(1):154-161.
78. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007, 335(7610):80.
79. Kruis W., Schutz E., Fric P., et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11(5):853-858.
80. Rembacken B.J., Snelling A.M., Hawkey P.M., et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354(9179):635-639.
81. Travis S.P., Stange E.F., Lemann M., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008, 2(1):24-62.
82. Ishikawa H., Matsumoto S., Ohashi Y., et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion 2011, 84(2):128-133.
83. Zocco M.A., Dal Verme L.Z., Cremonini F., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006, 23(11):1567-1574.
84. Tursi A., Brandimarte G., Papa A., et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010, 105(10):2218-2227.
85. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119(2):305-309.
86. Holubar S.D., Cima R.R., Sandborn W.J., et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010, (6). CD001176.
87. Gionchetti P., Rizzello F., Morselli C., et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007, 50(12):2075-2082. [discussion: 2082-4].
88. Guslandi M., Mezzi G., Sorghi M., et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000, 45(7):1462-1464.
89. Malchow H.A. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?. J Clin Gastroenterol 1997, 25(4):653-658.
90. Rolfe V.E., Fortun P.J., Hawkey C.J., et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006, (4). CD004826.
91. Van Gossum A., Dewit O., Louis E., et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 2007, 13(2):135-142.
92. Rahimi R., Nikfar S., Rahimi F., et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008, 53(9):2524-2531.
93. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4(1):28-62.
94. Castiglione F., Rispo A., Di Girolamo E., et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18(11-12):1107-1112.
95. Lauritano E.C., Gabrielli M., Scarpellini E., et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009, 13(2):111-116.
96. Majewski M., Reddymasu S.C., Sostarich S., et al. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007, 333(5):266-270.
97. Scarpellini E., Gabrielli M., Lauritano C.E., et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007, 25(7):781-786.
98. Gabrielli M., Lauritano E.C., Scarpellini E., et al. Bacillus clausii as a treatment of small intestinal bacterial overgrowth. Am J Gastroenterol 2009, 104(5):1327-1328.
99. Schey R., Rao S.S. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. Expert Rev Gastroenterol Hepatol 2011, 5(4):461-464.
100. Pimentel M., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011, 364(1):22-32.
101. Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011, 4:43-48.
102. Pimentel M., Park S., Mirocha J., et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006, 145(8):557-563.
103. Cheng J., Shah Y.M., Ma X., et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010, 335(1):32-41.
104. Colombel J.F., Lemann M., Cassagnou M., et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999, 94(3):674-678.
105. Thia K.T., Mahadevan U., Feagan B.G., et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009, 15(1):17-24.
106. Ursing B., Alm T., Barany F., et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982, 83(3):550-562.
107. Prantera C., Zannoni F., Scribano M.L., et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996, 91(2):328-332.
108. Ishikawa T., Okamura S., Oshimoto H., et al. Metronidazole plus ciprofloxacin therapy for active Crohn's disease. Intern Med 2003, 42(4):318-321.
109. Levine A., Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. J Crohns Colitis 2011, 5(3):222-226.
110. Selby W., Pavli P., Crotty B., et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007, 132(7):2313-2319.
111. Rutgeerts P., Hiele M., Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995, 108(6):1617-1621.
112. D'Haens G.R., Vermeire S., Van Assche G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008, 135(4):1123-1129.
113. Rutgeerts P., Van Assche G., Vermeire S., et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005, 128(4):856-861.
114. Ohkusa T., Nomura T., Terai T., et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005, 40(11):1334-1342.
115. Uehara T., Kato K., Ohkusa T., et al. Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. J Gastroenterol Hepatol 2010, 25(Suppl 1):S62-S66.
116. Turunen U.M., Farkkila M.A., Hakala K., et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998, 115(5):1072-1078.
117. Shen B., Achkar J.P., Lashner B.A., et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001, 7(4):301-305.
118. Shen B., Fazio V.W., Remzi F.H., et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007, 50(4):498-508.
119. Gionchetti P., Rizzello F., Venturi A., et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999, 13(6):713-718.